Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

The team identified more than 7,200 babies eligible to have received nirsevimab during its inaugural 2023-24 RSV season. But ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

The new injection, Nirsevimab, will be given to high-risk babies, including those born too early to be protected by the RSV ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...

Like nirsevimab, it’s an antibody that can reduce infections with the virus—but unlike nirsevimab, which is just a single shot, palivzumab requires monthly injections throughout the RSV season.

Nirsevimab reduced respiratory syncytial virus lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent 1 Results published in New England Journal of Medicine ...